Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer - A Cancer and Leukemia Group B study

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8109-8113

  Ross, Robert W ^a   Halabi, Susan ^b   Ou, San San ^b   Rajeshkumar, Barur R ^c   Woda, Bruce A ^c   Vogelzang, Nicholas J ^d,f   Small, Eric J ^e   Taplin, Mary Ellen ^a   Kantoff, Philip W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NEVADA CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; HEMOGLOBIN; IMATINIB; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CASTRATION; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ILIAC CREST; IMAGE ANALYSIS; LABORATORY DIAGNOSIS; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL; SURVIVAL TIME;

AGED; BIOPSY; BONE MARROW; BONE MARROW EXAMINATION; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 28144435545     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1250     Document Type: Article

References (24)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16.
4. Rohr K, Hegglin R. Tumorzellen im sternalpunkat. Deutsch Arch Klin Med 1936;179:61-79.
5. Chua DT, Ackermann W, Veenema RJ. Bone marrow biopsy in patients with carcinoma of the prostate. J Urol 1969;102:602-6.
6. Crisp J. Random bone marrow biopsy in the staging of carcinoma of the prostate. Br J Urol 1976;48: 265-7.
7. Mehan DJ, Broun GO, Jr., Hoover B, Storey G. Bone marrow findings in carcinoma of the prostate. J Urol 1966;95:241-4.
8. Nelson CM, Boatman DL, Flocks RH. Bone marrow examination in carcinoma of the prostate. J Urol 1973; 109:667-70.
9. Spiers AS, Deal DR, Kasimis BS, Miller BR. Evaluation of the bones and bone marrow in patients with metastatic carcinoma of the prostate: radiologic, cytologic and cytogenetic findings. J Med 1982;13:303-7.
10. Sy FA, Gursel EO, Veenema RJ. Positive random iliac bone biopsy in advanced prostatic cancer. Urology 1973;2:125-7.
11. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22: 1025-33.
12. Levine EG, Halabi S, Roberts JD, et al. Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. Cancer 2002;94:665-72.
13. Savarese DM, Halabi S, HarsV, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19:2509-16.
14. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21:2673-8.
15. Agresti A. A survey of exact inference for contingency tables. Stat Sci 1992;7:131-53.
16. Agresti A. Categorical data analysis. 1st ed. New York: Wiley: 1990.
17. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
18. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
19. Kaplan E, Meier P, Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
20. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient II. Analysis and examples. Br J Cancer 1977;35:1-39.
21. Welch J, Mackinnery C. Experience with aspiration biopsies of the bone marrow in the diagnosis and prognosis of carcinoma of the prostate gland. Am J Clin Pathol 1964;41:509-12.
22. Varenhorst E, Alund G, Lindstrom E, Manson JC. Bone marrow aspiration biopsy and bone scanning in the staging of prostatic cancer. Br J Urol 1983;55: 534-7.
23. Brown RS, Dogan A, Ell PJ, Payne HA, Masters JR, Harland SJ. The comparative values of bone marrow aspirate and trephine for obtaining bone scan-targeted metastases from hormone-refractory prostate cancer. Prostate Cancer Prostatic Dis 2002;5:144-51.
24. Bearden JD, Ratkin GA, Coltman CA. Comparison of the diagnostic value of bone marrow biopsy and bone marrow aspiration in neoplastic disease. J Clin Pathol 1974;27:738-40.